Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090310 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT01090310 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT01090310, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
Interventions
- DRUG Placebo
- DRUG AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090310
The ClinicalTrials.gov registry entry for NCT01090310 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01090310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090310 about?
NCT01090310 is a clinical study titled "Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis". This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
What is the current status of trial NCT01090310?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2010-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01090310?
The interventions under investigation include: Placebo (DRUG), AIN457 (DRUG).
Who is sponsoring clinical trial NCT01090310?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.